PLEASANTON, CA--(MARKET WIRE)--Jul 30, 2007 -- Lipid Sciences, Inc. (NasdaqGM:LIPD - News) today reported that enrollment is complete for two-thirds, or 20 out of a total target of 30 patients, in the Company’s safety and feasibility clinical trial of HDL Selective Delipidation at the Washington Hospital Center in Washington, D.C.
